People

Clive Meanwell gives way to new CEO as activist investor Alex Denner shakes up The Medicines Company

Alex Denner has made his first public move at The Medicines Company since consolidating power on the board — and it’s a big one.

Clive Meanwell passing the CEO role and his board seat to Merck vet Mark Timney, leaving a position he’s occupied for the better part of the company’s 22-year history.

He’s not out entirely. In the newly-created role of chief innovation officer, he is tasked with supporting the ongoing development of inclisiran — the biotech’s experimental LDL-lowering RNAi therapy in-licensed from Alnylam.


In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 37,400+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,400+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Director, Program Management
Contrafect Corporation New York, NY
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA

Visit Endpoints Careers ->